Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

5056

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure With Preserved Ejection Fraction
Heart Failure With Mildly Reduced Ejection Fraction
Obesity

Interventions

DRUG: Maridebart cafraglutide
DRUG: Placebo

Sponsor

Amgen